DE69739253D1 - Liposomaler grippeimpfstoff und verfahren - Google Patents

Liposomaler grippeimpfstoff und verfahren

Info

Publication number
DE69739253D1
DE69739253D1 DE69739253T DE69739253T DE69739253D1 DE 69739253 D1 DE69739253 D1 DE 69739253D1 DE 69739253 T DE69739253 T DE 69739253T DE 69739253 T DE69739253 T DE 69739253T DE 69739253 D1 DE69739253 D1 DE 69739253D1
Authority
DE
Germany
Prior art keywords
liposomal
vaccine
grip
vaccines
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739253T
Other languages
German (de)
English (en)
Inventor
Eliezer Kedar
Ilan Babai
Yechezkel Barenholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of DE69739253D1 publication Critical patent/DE69739253D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69739253T 1996-06-24 1997-06-24 Liposomaler grippeimpfstoff und verfahren Expired - Lifetime DE69739253D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2006396P 1996-06-24 1996-06-24
PCT/IL1997/000210 WO1997049423A2 (en) 1996-06-24 1997-06-24 Liposomal influenza vaccine composition and method

Publications (1)

Publication Number Publication Date
DE69739253D1 true DE69739253D1 (de) 2009-03-26

Family

ID=21796541

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739253T Expired - Lifetime DE69739253D1 (de) 1996-06-24 1997-06-24 Liposomaler grippeimpfstoff und verfahren

Country Status (8)

Country Link
US (1) US5919480A (enExample)
EP (1) EP0954286B1 (enExample)
JP (2) JP4227195B2 (enExample)
AT (1) ATE422352T1 (enExample)
AU (1) AU731705B2 (enExample)
CA (1) CA2258878C (enExample)
DE (1) DE69739253D1 (enExample)
WO (1) WO1997049423A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731972B1 (en) * 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
JP2001521908A (ja) * 1997-10-31 2001-11-13 シストロン バイオテクノロジー インク． ワクチンアジュバントとして有用な封入された免疫調節物質
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
WO2002038175A1 (en) * 2000-11-07 2002-05-16 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
US7662619B2 (en) * 2000-11-15 2010-02-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Sol-fusin: use of GP64-6His to catalyze membrane fusion
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
IL159334A0 (en) * 2001-06-25 2004-06-01 Yissum Res Dev Co A method for preparation of vesicles loaded with biological material and different uses thereof
DE60232413D1 (en) * 2001-07-05 2009-07-02 Ltb4 Sweden Ab Ltb4 als adjuvans für impfstoffe
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US20040208920A1 (en) * 2002-07-03 2004-10-21 Dov Michaeli Liposomal vaccine
CA2523413A1 (en) 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
WO2004100928A1 (de) * 2003-05-09 2004-11-25 Novosom Ag Injizierbare liposomale depots zum wirkstoffdelivery
EP1666059A4 (en) * 2003-08-11 2008-08-27 Univ Osaka Res Found NEW VACCINE WITH AN ADJUVANS FOR TRIGGERING ABSORBENT IMMUNITY
CN102172397B (zh) * 2003-08-21 2013-01-30 利普泰克有限公司 树突细胞的体内靶向
FR2868951B1 (fr) * 2004-04-15 2006-07-21 Ethypharm Sa Compositions contenant ds vesicules lamellaires incorporant un principe actif peu soluble dans l'eau et produits intermediaires utiles pour leur preparation
US20050260260A1 (en) * 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
WO2006074303A2 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CN106310293A (zh) * 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2231180B1 (en) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
AU2009272280B2 (en) * 2008-07-14 2015-08-06 Polypid Ltd. Sustained-release drug carrier composition
EP2391370B1 (en) 2009-02-02 2015-06-03 Galmed Research and Development Ltd. Methods and compositions for treating alzheimer's disease
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
ES2573427T3 (es) 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
IN2012DN00570A (enExample) 2009-07-14 2015-06-12 Polypid Ltd
AU2010303568B2 (en) * 2009-10-09 2014-07-31 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
CA2783001C (en) 2010-01-19 2017-12-12 Polypid Ltd. Sustained-release nucleic acid matrix compositions
CA2840079C (en) * 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CN107296792B (zh) 2011-01-13 2021-07-27 变异生物技术公司 囊泡及由其产生之制剂的制备方法
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CN103998058B (zh) 2011-10-06 2021-11-05 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
EP2780350B1 (en) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN103736090B (zh) * 2014-01-27 2016-03-02 中国医学科学院医学生物学研究所 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗
CN110151702A (zh) * 2019-06-24 2019-08-23 昆明医科大学 聚乙二醇修饰流感疫苗脂质体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
AU627226B2 (en) * 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3037994B2 (ja) * 1989-11-02 2000-05-08 テルモ株式会社 リポソーム表面への蛋白質吸着抑制剤
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JPH07504683A (ja) * 1992-07-08 1995-05-25 シェリング・コーポレーション Ｇｍ−ｃｓｆのワクチンアジュバントとしての利用
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
WO1995004524A1 (en) * 1993-08-06 1995-02-16 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity

Also Published As

Publication number Publication date
EP0954286B1 (en) 2009-02-11
CA2258878C (en) 2008-03-18
JP4227195B2 (ja) 2009-02-18
WO1997049423A2 (en) 1997-12-31
US5919480A (en) 1999-07-06
AU3188297A (en) 1998-01-14
AU731705B2 (en) 2001-04-05
WO1997049423A3 (en) 1998-02-19
JP2008260779A (ja) 2008-10-30
EP0954286A2 (en) 1999-11-10
CA2258878A1 (en) 1997-12-31
JP2000513352A (ja) 2000-10-10
ATE422352T1 (de) 2009-02-15

Similar Documents

Publication Publication Date Title
DE69739253D1 (de) Liposomaler grippeimpfstoff und verfahren
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
FI953608L (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella
AU4188100A (en) Dry formulation for transcutaneous immunization
EP1162272A3 (en) Generation of immune responses to prostate-specific antigen (SPA)
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
DE68921389D1 (de) Influenzaimpfstoff und Adjuvanten.
WO1995020660A3 (en) Immunization by inoculation of dna transcription unit
WO1999002183A3 (en) A method of inducing a ctl response
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
WO2001034801A3 (en) Recombinant gelatin in vaccines
EP0705109A4 (en) ADJUVANTIES FOR VACCINE AGAINST THE RESPIRATORY SYNCITIAL VIRUS
EP1964573A3 (en) Method of inducing and/or enhancing an immune response to tumor antigens
BR9506885A (pt) Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
DK0765333T3 (da) Quillajasaponinadjuvans og vaccineformulering, der indeholder denne
EP1932915A3 (en) Materials and methods relating to improved vaccination strategies
AU2981395A (en) Method of identifying and producing antigen peptides and use thereof as vaccines
AU2901997A (en) Immunogenic complex, use, method of preparation thereof and vaccine containing same
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
EP0320034A3 (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.
PL341528A1 (en) Vaccine with overproduction of a homologous antigen and method of obtaining same
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition